Bispecific T cell engagers (BiTEs) fall into the second group (103), independently activating T-cells to drive cytotoxicity, cytokine release, and B-cell activation by targeting both a tumor antigen and CD3e, leading to T-cell-dependent tumor cell destruction (103–105). Here, CD3E is linked to neoplasm.